NO961423L - Oligopeptider avledet fra C-reaktive proteinfragmenter - Google Patents
Oligopeptider avledet fra C-reaktive proteinfragmenterInfo
- Publication number
- NO961423L NO961423L NO961423A NO961423A NO961423L NO 961423 L NO961423 L NO 961423L NO 961423 A NO961423 A NO 961423A NO 961423 A NO961423 A NO 961423A NO 961423 L NO961423 L NO 961423L
- Authority
- NO
- Norway
- Prior art keywords
- group
- amino acid
- leucine
- absent
- acid residue
- Prior art date
Links
- 102100032752 C-reactive protein Human genes 0.000 title abstract 3
- 102000015636 Oligopeptides Human genes 0.000 title abstract 3
- 108010038807 Oligopeptides Proteins 0.000 title abstract 3
- 108010074051 C-Reactive Protein Proteins 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 title abstract 2
- 125000000539 amino acid group Chemical group 0.000 abstract 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 3
- 229960003136 leucine Drugs 0.000 abstract 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 2
- QYPPJABKJHAVHS-UHFFFAOYSA-P agmatinium(2+) Chemical group NC(=[NH2+])NCCCC[NH3+] QYPPJABKJHAVHS-UHFFFAOYSA-P 0.000 abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 229960000310 isoleucine Drugs 0.000 abstract 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 abstract 2
- 229960004295 valine Drugs 0.000 abstract 2
- 239000004474 valine Substances 0.000 abstract 2
- OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 239000004475 Arginine Substances 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical group NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 abstract 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 1
- 239000004472 Lysine Chemical group 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical group NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Chemical group NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 abstract 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Chemical group OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 abstract 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 1
- 108010077895 Sarcosine Proteins 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229960003767 alanine Drugs 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 1
- 229960002449 glycine Drugs 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
- 229960003646 lysine Drugs 0.000 abstract 1
- 229960003104 ornithine Drugs 0.000 abstract 1
- 229960002429 proline Drugs 0.000 abstract 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940043230 sarcosine Drugs 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 229960002898 threonine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4737—C-reactive protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Det er beskrevet oligopeptider avledet fra fragment- er av C-reaktivt protein (nedenfor CRP) og deres anvendelse som immunomodulerende midler og ved tera- pi av kardiovaskulære og inflammatoriske sykdommer. Oligopeptidene har formelen: AI-AJ-A3-A, hvori A,, er et aminosyreresiduum valgt fra gruppen omfat- tende glycin, treonin, leucin, isoleucin, valin, sarko- cin, alanin, (Cj.6)acylglycin, eller er fraværende; A, er et aminosyreresiduum valgt fra gruppen omfattende leucin, isoleucin, valin, lysin, ornitin, eventuelt N a- substituert med minst (Cn) alkyl, benzyl eller (C2.6)acyl- gruppe eller er et prolinresiduum, eller er fraværende; A3 er et aminosyreresiduum valgt fra gruppen omfattende prolin, leucin, isoleucin og valin; A« er et aminosyreresiduum valgt fra gruppen omfattende arginin, leucin og glutamin, eventuelt amidert ved sin C- terminale posisjon, eller er et agmatinresiduum, eller er fraværende, med det forbehold at kun en av Al( Aj og A, kan være fraværende idet nevnte forbindelser er ytter- ligere ^karakterisert ved at gruppene av side- ! kjedene av nevnte aminosyreresiduer og av agmatinresiduer ! eventuelt kan være substituert med en eller flere substi- ¿ tuenter valgt fra gruppen omfattende (Ci.,)alkyl, benzyl 1 eller (C2.6)acyl, og hver av de tidligere nevnte residuer kan være i D eller L form på karbonatomet som bærer side- kjeden eller i form av en av de mulige diastereomerer eller enantiomerer, samt farmasøytisk akseptable syre- eller basesalter derav.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI932154A IT1271486B (it) | 1993-10-12 | 1993-10-12 | Oligopeptidi immunomodulatori derivati di frammenti della proteina c- reattiva |
| PCT/EP1994/001574 WO1995010531A1 (en) | 1993-10-12 | 1994-05-16 | Oligopeptides derived from c-reactive protein fragments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO961423D0 NO961423D0 (no) | 1996-04-11 |
| NO961423L true NO961423L (no) | 1996-06-10 |
Family
ID=11367010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO961423A NO961423L (no) | 1993-10-12 | 1996-04-11 | Oligopeptider avledet fra C-reaktive proteinfragmenter |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6057295A (no) |
| EP (1) | EP0723552B1 (no) |
| JP (1) | JP3221881B2 (no) |
| KR (1) | KR100363408B1 (no) |
| CN (1) | CN1041524C (no) |
| AT (1) | ATE226591T1 (no) |
| AU (1) | AU684511B2 (no) |
| CA (1) | CA2173939C (no) |
| DE (1) | DE69431603T2 (no) |
| DK (1) | DK0723552T3 (no) |
| ES (1) | ES2185652T3 (no) |
| FI (1) | FI961584A0 (no) |
| HU (1) | HUT75538A (no) |
| IL (1) | IL109761A0 (no) |
| IT (1) | IT1271486B (no) |
| NO (1) | NO961423L (no) |
| PT (1) | PT723552E (no) |
| WO (1) | WO1995010531A1 (no) |
| ZA (1) | ZA943610B (no) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6342481B1 (en) * | 1993-10-12 | 2002-01-29 | Italfarmaco S.P.A. | Oligopeptides derived from C-reactive protein fragments |
| EP1408031A1 (en) * | 2002-10-09 | 2004-04-14 | 3 D Gene Pharma | Pyrolidine derivatives useful in treatment of hepatitis C virus infection |
| WO2010033207A1 (en) | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of therapeutic peptides |
| IN2012DN06589A (no) | 2010-01-19 | 2015-10-23 | Harvard College | |
| JP2014523914A (ja) | 2011-07-18 | 2014-09-18 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 操作された微生物標的化分子およびその使用 |
| EP2976642A4 (en) | 2013-03-15 | 2016-09-21 | Harvard College | METHODS AND COMPOSITIONS FOR IMPROVING THE DETECTION AND / OR CAPTURE OF A TARGET ENTITY |
| CA2913155A1 (en) | 2013-05-21 | 2014-11-27 | President And Fellows Of Harvard College | Engineered heme-binding compositions and uses thereof |
| EP3083658B1 (en) | 2013-12-18 | 2019-05-08 | President and Fellows of Harvard College | Crp capture/detection of gram positive bacteria |
| CN108289928A (zh) | 2015-08-06 | 2018-07-17 | 哈佛大学校长及研究员协会 | 改进的微生物-结合分子和其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2945239A1 (de) * | 1979-11-09 | 1981-05-21 | Troponwerke GmbH & Co KG, 5000 Köln | Oligopeptide, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
| US4353823A (en) * | 1981-09-01 | 1982-10-12 | Chipens Gunar I | Synthetic analog of tuftisin |
| GB8525615D0 (en) * | 1985-10-17 | 1985-11-20 | Hoffmann La Roche | Polypeptides |
| ES2052517T3 (es) * | 1986-07-16 | 1994-07-16 | Eniricerche Spa | Analogos de tuftsina parcialmente retroinversos, metodo de preparacion de los mismos y composiciones farmaceuticas que los contienen. |
| IT1254883B (it) * | 1992-04-16 | 1995-10-11 | Italfarmaco Spa | Tetrapeptidi parzialmente modificati e retroinvertiti, analoghi di frammenti della proteina c-reattiva. |
-
1993
- 1993-10-12 IT ITMI932154A patent/IT1271486B/it active IP Right Grant
-
1994
- 1994-05-16 JP JP50541495A patent/JP3221881B2/ja not_active Expired - Fee Related
- 1994-05-16 AT AT94916966T patent/ATE226591T1/de not_active IP Right Cessation
- 1994-05-16 WO PCT/EP1994/001574 patent/WO1995010531A1/en active IP Right Grant
- 1994-05-16 US US08/624,405 patent/US6057295A/en not_active Expired - Fee Related
- 1994-05-16 CN CN94193726A patent/CN1041524C/zh not_active Expired - Fee Related
- 1994-05-16 DK DK94916966T patent/DK0723552T3/da active
- 1994-05-16 HU HU9600934A patent/HUT75538A/hu unknown
- 1994-05-16 ES ES94916966T patent/ES2185652T3/es not_active Expired - Lifetime
- 1994-05-16 KR KR1019960701879A patent/KR100363408B1/ko not_active IP Right Cessation
- 1994-05-16 CA CA002173939A patent/CA2173939C/en not_active Expired - Fee Related
- 1994-05-16 PT PT94916966T patent/PT723552E/pt unknown
- 1994-05-16 EP EP94916966A patent/EP0723552B1/en not_active Expired - Lifetime
- 1994-05-16 DE DE69431603T patent/DE69431603T2/de not_active Expired - Fee Related
- 1994-05-16 AU AU68441/94A patent/AU684511B2/en not_active Ceased
- 1994-05-24 ZA ZA943610A patent/ZA943610B/xx unknown
- 1994-05-24 IL IL10976194A patent/IL109761A0/xx unknown
-
1996
- 1996-04-11 NO NO961423A patent/NO961423L/no unknown
- 1996-04-11 FI FI961584A patent/FI961584A0/fi not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PT723552E (pt) | 2003-02-28 |
| ITMI932154A1 (it) | 1995-04-12 |
| CA2173939C (en) | 2002-08-27 |
| KR100363408B1 (ko) | 2003-02-11 |
| FI961584A (fi) | 1996-04-11 |
| ATE226591T1 (de) | 2002-11-15 |
| DK0723552T3 (da) | 2003-02-24 |
| ITMI932154A0 (it) | 1993-10-12 |
| AU6844194A (en) | 1995-05-04 |
| FI961584A0 (fi) | 1996-04-11 |
| EP0723552A1 (en) | 1996-07-31 |
| JPH09503200A (ja) | 1997-03-31 |
| CA2173939A1 (en) | 1995-04-20 |
| WO1995010531A1 (en) | 1995-04-20 |
| HUT75538A (en) | 1997-05-28 |
| EP0723552B1 (en) | 2002-10-23 |
| AU684511B2 (en) | 1997-12-18 |
| US6057295A (en) | 2000-05-02 |
| IT1271486B (it) | 1997-05-28 |
| IL109761A0 (en) | 1994-08-26 |
| ES2185652T3 (es) | 2003-05-01 |
| JP3221881B2 (ja) | 2001-10-22 |
| HU9600934D0 (en) | 1996-08-28 |
| DE69431603D1 (de) | 2002-11-28 |
| ZA943610B (en) | 1995-01-25 |
| CN1133048A (zh) | 1996-10-09 |
| NO961423D0 (no) | 1996-04-11 |
| DE69431603T2 (de) | 2003-03-13 |
| CN1041524C (zh) | 1999-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO961423L (no) | Oligopeptider avledet fra C-reaktive proteinfragmenter | |
| IE801342L (en) | Peptides | |
| AU544256B2 (en) | Novel acylpeptides | |
| HUP0004234A2 (hu) | Dolasztatin-15-származékok | |
| IL175319A0 (en) | Novel phosphate-binding protein, pharmaceutical compositions containing same and use thereof | |
| NO834340L (no) | Nye polypeptider | |
| KR900009694A (ko) | 급속히 분해가능한, hiv 프로테아제용 기질 | |
| KR970005043B1 (en) | Tumor necrosis factor alpha muteins | |
| CA2334941A1 (en) | Tnf-derived peptides for use in treating oedema | |
| MacKenzie et al. | Gas chromatography—mass spectrometry of the N (O)-heptafluorobutyryl isobutyl esters of the protein amino acids using electron impact ionisation | |
| DE68917837T2 (de) | Peptid-Verbindungen. | |
| AU671989B2 (en) | Treatment of tropical spastic paresis with peptide T | |
| Lu et al. | The primary structure of tubulin sequences of the carboxyl terminus and seven other cyanogen bromide peptides from the α-chain | |
| EP1609861A4 (en) | ION CHANNEL ACTIVITY INHIBITABLE LOW-MOLECULAR PEPTIDES | |
| NO921715L (no) | Nye polypeptider med affinitet for lipopolysakkarider og anvendelser derav | |
| DE3782880T2 (de) | Hemmende peptide. | |
| WO2003097678A3 (en) | Use of the repressor glxr for the synthesis of lysine in corynebacterium glutamicum | |
| AR026068A1 (es) | Peptidos modificados y peptidomimeticos para el uso en inmunoterapia. | |
| KR840006328A (ko) | 펩티드의 제조방법 | |
| GB992957A (en) | New decapeptides and their manufacture | |
| JPS5225768A (en) | Preparation of novel pentapeptides | |
| EP1878793A4 (en) | NOVEL PROTEIN AND PROPHYLACTIC / THERAPEUTIC DRUG AGAINST NEURODEGENERATIVE DISEASE SUCH AS POLYGLUTAMINE DISEASE INCLUDING SAID PROTEIN | |
| JPS562969A (en) | Cyclic peptide | |
| ES488822A0 (es) | Un procedimiento para la preparacion de un peptido. | |
| Barrett | Nomenclature of Amino Acids |